Search results
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks via Yahoo Finance· 13 hours agoApellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus...
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1
Proactive Investors· 13 hours agoDrawing from his background in ophthalmology at Johns Hopkins, O'Donnell explained that the drug is...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 2 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Santa J. Ono, University of Michigan President, Joins USJF Board
FOX 23 News Albany· 8 hours agoSanta J. Ono, president of the University of Michigan, has joined the United States-Japan Foundation...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 6 days agoThe paper-based KeepSight Journal from the International Macular and Retinal Foundation, Genentech's...
Scientists find potential treatment target for leading cause of blindness
Investing.com· 6 days agoNew Delhi, May 2 (IANS) US scientists have found answers to why treatment for neovascular...
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
Newswise· 5 days agoTwo treatments for retinal diseases, invented by Neena Haider, PhD, that currently are in clinical trials run by Ocugen, represent a conceptually broad, new approach that ...
...Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry...
Benzinga· 7 days agoLuxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
FOX 59 Indianapolis· 13 hours agoFood and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome is entitled to a Priority ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day ago(NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet ...